Advertisement
UK markets close in 6 hours 44 minutes
  • FTSE 100

    8,292.09
    +44.30 (+0.54%)
     
  • FTSE 250

    20,437.71
    +74.28 (+0.36%)
     
  • AIM

    767.60
    -0.43 (-0.06%)
     
  • GBP/EUR

    1.1845
    +0.0008 (+0.06%)
     
  • GBP/USD

    1.2669
    -0.0018 (-0.14%)
     
  • Bitcoin GBP

    48,563.46
    +633.83 (+1.32%)
     
  • CMC Crypto 200

    1,276.31
    -7.48 (-0.58%)
     
  • S&P 500

    5,469.30
    +21.43 (+0.39%)
     
  • DOW

    39,112.16
    -299.05 (-0.76%)
     
  • CRUDE OIL

    81.07
    +0.24 (+0.30%)
     
  • GOLD FUTURES

    2,327.50
    -3.30 (-0.14%)
     
  • NIKKEI 225

    39,667.07
    +493.92 (+1.26%)
     
  • HANG SENG

    18,089.93
    +17.03 (+0.09%)
     
  • DAX

    18,321.97
    +144.35 (+0.79%)
     
  • CAC 40

    7,686.94
    +24.64 (+0.32%)
     

Private companies own 34% of MedAdvisor Limited (ASX:MDR) shares but individual investors control 36% of the company

Key Insights

  • The considerable ownership by individual investors in MedAdvisor indicates that they collectively have a greater say in management and business strategy

  • The top 7 shareholders own 53% of the company

  • Institutions own 23% of MedAdvisor

If you want to know who really controls MedAdvisor Limited (ASX:MDR), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are individual investors with 36% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

Private companies, on the other hand, account for 34% of the company's stockholders.

ADVERTISEMENT

Let's delve deeper into each type of owner of MedAdvisor, beginning with the chart below.

View our latest analysis for MedAdvisor

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About MedAdvisor?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

We can see that MedAdvisor does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see MedAdvisor's historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
earnings-and-revenue-growth

We note that hedge funds don't have a meaningful investment in MedAdvisor. The Pharmacy Guild of Australia is currently the company's largest shareholder with 17% of shares outstanding. With 12% and 8.0% of the shares outstanding respectively, Perennial Value Management Limited and Cotiviti, Inc. are the second and third largest shareholders.

On further inspection, we found that more than half the company's shares are owned by the top 7 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of MedAdvisor

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

We can see that insiders own shares in MedAdvisor Limited. It has a market capitalization of just AU$242m, and insiders have AU$16m worth of shares, in their own names. Some would say this shows alignment of interests between shareholders and the board, though we generally prefer to see bigger insider holdings. But it might be worth checking if those insiders have been selling.

General Public Ownership

With a 36% ownership, the general public, mostly comprising of individual investors, have some degree of sway over MedAdvisor. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Company Ownership

We can see that Private Companies own 34%, of the shares on issue. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand MedAdvisor better, we need to consider many other factors.

I like to dive deeper into how a company has performed in the past. You can access this interactive graph of past earnings, revenue and cash flow, for free.

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com